Novartis: Kisqali Shows Clinically Meaningful Overall Survival In Broadest HR+/HER2- Early Breast Cancer Population At High Risk Of Recurrence
READ HERE
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Novartis Says Kisqali Shows Meaningful Overall Survival in Early Breast Cancer
Novartis said Kisqali showed clinically meaningful overall survival in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence.